1. Home
  2. ENTA vs ECF Comparison

ENTA vs ECF Comparison

Compare ENTA & ECF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ENTA
  • ECF
  • Stock Information
  • Founded
  • ENTA 1995
  • ECF 1986
  • Country
  • ENTA United States
  • ECF United States
  • Employees
  • ENTA N/A
  • ECF N/A
  • Industry
  • ENTA Biotechnology: Pharmaceutical Preparations
  • ECF Finance/Investors Services
  • Sector
  • ENTA Health Care
  • ECF Finance
  • Exchange
  • ENTA Nasdaq
  • ECF Nasdaq
  • Market Cap
  • ENTA 127.8M
  • ECF 136.5M
  • IPO Year
  • ENTA 2013
  • ECF N/A
  • Fundamental
  • Price
  • ENTA $6.28
  • ECF $9.58
  • Analyst Decision
  • ENTA Buy
  • ECF
  • Analyst Count
  • ENTA 4
  • ECF 0
  • Target Price
  • ENTA $19.50
  • ECF N/A
  • AVG Volume (30 Days)
  • ENTA 537.1K
  • ECF 57.7K
  • Earning Date
  • ENTA 02-05-2025
  • ECF 01-01-0001
  • Dividend Yield
  • ENTA N/A
  • ECF 6.42%
  • EPS Growth
  • ENTA N/A
  • ECF N/A
  • EPS
  • ENTA N/A
  • ECF 0.46
  • Revenue
  • ENTA $67,635,000.00
  • ECF N/A
  • Revenue This Year
  • ENTA $11.80
  • ECF N/A
  • Revenue Next Year
  • ENTA $3.99
  • ECF N/A
  • P/E Ratio
  • ENTA N/A
  • ECF $17.61
  • Revenue Growth
  • ENTA N/A
  • ECF N/A
  • 52 Week Low
  • ENTA $5.70
  • ECF $7.02
  • 52 Week High
  • ENTA $17.80
  • ECF $8.91
  • Technical
  • Relative Strength Index (RSI)
  • ENTA 31.04
  • ECF 42.15
  • Support Level
  • ENTA $5.70
  • ECF $9.48
  • Resistance Level
  • ENTA $6.56
  • ECF $9.93
  • Average True Range (ATR)
  • ENTA 0.74
  • ECF 0.10
  • MACD
  • ENTA -0.11
  • ECF -0.06
  • Stochastic Oscillator
  • ENTA 14.91
  • ECF 18.18

About ENTA Enanta Pharmaceuticals Inc.

Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.

About ECF Ellsworth Growth and Income Fund Ltd.

Ellsworth Growth and Income Fund Ltd operate as a closed-end, diversified management investment company. Its investment objective is to provide income and the potential for capital appreciation, which objectives the Fund considers to be relatively equal over the long term due to the nature of the securities in which it invests. The company invests in convertible and equity securities. It invests in various sectors, such as healthcare, financial services, computer software and services, energy and utilities, real estate investment trusts, semiconductors, telecommunications, business services, food and beverage, consumer products, transportation, consumer services among others.

Share on Social Networks: